Answers are grounded in this paper and cite their sources.
Preclinical study demonstrates potent antibacterial efficacy and favorable metabolic disposition of DL-8280, suggesting promise for treating systemic infections.
As part of a search for new synthetic antibacterial agents to combat systemic infection, various analogues of 7-oxo-2, 3-dihydro-7H-pyrido [1, 2, 3-de] [1, 4] benzoxazine-6-carboxylic acids were synthesized. Among the compounds newly synthesized, 9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2, 3-dihydro-7H-pyrido [1, 2, 3-de] [1, 4] benzoxazine-6-carboxylic acid (DL-8280) showed potent antibacterial activity against Gram-positive and-negative pathogens, including Psedomonas aeruginosa, and its metabolic disposition was shown in separate experimentals to be favorable.
No takes yet. Share an insight, caveat, or question.
Hayakawa et al. (1984) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: